Oncolytic viruses: overcoming translational challenges

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Oncolytic virotherapy (OVT) utilizes viruses to selectively target and eliminate tumor cells.
• Despite promising preclinical data, clinical translation of OVT faces challenges in viral delivery, spread, resistance, and host immunity.
• Overcoming these limitations is crucial for advancing OVT as a cancer therapy.

Purpose of the Study:

• To review and highlight innovative strategies for overcoming key obstacles in oncolytic virotherapy.
• To discuss advancements in engineering oncolytic viruses (OVs) for enhanced tumor targeting and immune system evasion.
• To explore novel delivery systems and combination therapies to improve OVT efficacy.

Main Methods:

• Review of recent research and clinical trial data on oncolytic viruses (OVs).
• Focus on engineering strategies for improved OV targeting, immune evasion, and delivery.
• Analysis of combination approaches involving OVT and other immunotherapeutic agents.
• Emphasis on the role of clinically relevant mouse tumor models.

Main Results:

• Engineered OVs demonstrate improved tumor cell targeting and reduced immunogenicity.
• Novel delivery systems show potential for enhanced viral biodistribution and tumor penetration.
• Combination therapies, particularly with other immunotherapies, exhibit synergistic anti-tumor effects.
• Clinically translatable models facilitate more accurate prediction of therapeutic outcomes.

Conclusions:

• Strategic engineering of OVs, improved delivery methods, and combination therapies are key to overcoming clinical limitations.
• Further research utilizing robust preclinical models is essential for successful translation of OVT into effective cancer treatments.
• Oncolytic virotherapy holds significant promise as a component of future cancer treatment regimens.